# Hospital Inpatient Coding

## Aortic fixation in conjunction with primary placement of stent graft

<table>
<thead>
<tr>
<th>ICD-10 Procedure Code</th>
<th>Description</th>
<th>FY2021 MS-DRG Assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Do not code separately</td>
<td>Reimbursed with principal procedure (EVAR or TEVAR repair)</td>
</tr>
</tbody>
</table>

## Aortic fixation without placement of stent graft (revision)

### EVAR Revision

<table>
<thead>
<tr>
<th>ICD-10 Procedure Code</th>
<th>Description</th>
<th>FY2021 MS-DRG Assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>04WY3DZ</td>
<td>Revision of Intraluminal Device in Lower Artery, percutaneous approach</td>
<td>252-254: Other Vascular Procedures</td>
</tr>
</tbody>
</table>

### TEVAR Revision

<table>
<thead>
<tr>
<th>ICD-10 Procedure Code</th>
<th>Description</th>
<th>FY2021 MS-DRG Assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>02WY3DZ</td>
<td>Revision of Intraluminal Device in Great Vessel, Percutaneous Approach</td>
<td>270-272: Other Major Cardiovascular Procedures</td>
</tr>
</tbody>
</table>

# Physician Coding

## Aortic fixation

<table>
<thead>
<tr>
<th>CPT® Code</th>
<th>Description</th>
<th>2021 Work RVUs</th>
<th>2021 Total RVUs</th>
</tr>
</thead>
<tbody>
<tr>
<td>34712</td>
<td>Transcatheter delivery of enhanced fixation device(s) to the endograft (eg, anchor, screw, tack) and all associated radiological supervision and interpretation</td>
<td>12.00</td>
<td>19.33</td>
</tr>
</tbody>
</table>

- This code should be reported only once per operative session, even when multiple anchors are placed.
- 34712 is subject to the multiple procedure payment reduction (modifier –51).

---

Please contact our Reimbursement Team with questions
1.877.347.9662
rs.cardiovascularhealtheconomics@medtronic.com

These suggestions do not replace seeking coding advice from the payer and/or your coding staff, the provider of services is ultimately responsible for correct coding.
**Indications for Use:** The Heli-FX™ EndoAnchor™ system is intended to provide fixation and sealing between endovascular aortic grafts and the native artery. The Heli-FX™ EndoAnchor™ system is indicated for use in patients whose endovascular grafts have exhibited migration or endoleak, or are at risk of such complications, in whom augmented radial fixation and/or sealing is required to regain or maintain adequate aneurysm exclusion. The EndoAnchor™ implant may be implanted at the time of the initial endograft placement, or during a secondary (i.e. repair) procedure.

**Contraindications:** Treatment with the Heli-FX™ EndoAnchor™ system is contraindicated for use in the following circumstances:

- In patients with known allergies to the EndoAnchor™ implant material (MP35N-LT)
- In conjunction with the Endologix Powerlink™ endograft

**Warnings:**

- The long-term performance of the EndoAnchor™ implant has not been established. All patients should be advised of the need for long-term, regular follow-up visits to assess the patient’s health status and endograft performance. The EndoAnchor™ implant does not reduce this requirement.
- The EndoAnchor™ implant and the Heli-FX™ EndoAnchor™ system have been evaluated in vitro testing and determined to be compatible with the Cook Zenith™, Cook Zenith™ TX2™, Gore Excluder™, Gore TAG™, Medtronic AneuRx™, Medtronic Endurant™, Medtronic Talent™ AAA, Medtronic Talent™ TAA, Medtronic Valiant Xcelerant™, Medtronic Valiant™ Captivia™, and Medtronic Valiant Navion™ endografts. Use with endografts other than those listed above has not been evaluated.
- The performance of the EndoAnchor™ implant has not been evaluated for securing multiple endograft components together. Not securing EndoAnchor™ implants into aortic tissue could result in graft fabric damage, component separation, and resultant Type III endoleaks.
- The performance of the EndoAnchor™ implant has not been evaluated in vessels other than the aorta. Use of the EndoAnchor™ implant to secure endografts to other vessels may result in adverse patient consequences such as vascular perforation, bleeding, or damage to adjacent structures.
- The performance of the EndoAnchor™ implant has not been evaluated for securing multiple anatomical structures together. Such use could result in adverse patient consequences such as vascular perforation, bleeding, or embolic events.

**MRI Safety and Compatibility:**

- The EndoAnchor™ implants have been determined to be MR Conditional at 3T or less when the scanner is in Normal Operating Mode with whole-body-averaged SAR of 2 W/kg, or in First Level Controlled Mode with a maximum whole-body-averaged SAR of 4 W/kg.
- Please refer to documentation provided by the endograft system manufacturer for MR safety status of the endograft system with which the EndoAnchor™ implants are being used.

**Potential Adverse Events:** Possible adverse events that are associated with the Heli-FX™ EndoAnchor™ system, include, but are not limited to:

- Aneurysm rupture
- Death
- EndoAnchor™ implant embolization
- Endoleaks (Type III)
- Enteric fistula
- Failure to correct/prevent Type I endoleak
- Failure to prevent endograft migration
- Infection
- Renal complications (renal artery occlusion/dissection or contrast-induced acute kidney injury)
- Stroke
- Surgical conversion to open repair
- Vascular access complications, including infection, pain, hematoma, pseudoaneurysm, arteriovenous fistula
- Vessel damage, including dissection, perforation, and spasm

Please refer to documentation provided by the endograft system with which the EndoAnchor™ implants are being used. Additional potential adverse events may be associated with endovascular aneurysm repair in general. Refer to the Instructions for Use provided with the endograft for additional potential adverse events.

**CAUTION:** Federal (USA) law restricts these devices to sale by or on the order of a licensed healthcare practitioner. See package inserts for full product information.

**CAUTION:** EndoAnchor™ implant locations should be based upon a detailed examination of the preoperative CT imaging in cases involving irregular or eccentric plaque in the intended sealing zones. EndoAnchor™ implants should be implanted only into areas of aortic tissue free of calcified plaque or thrombus, where such pathology is diffuse and less than 2mm in thickness. Attempting to place EndoAnchor™ implants into more severe plaque or thrombus may be associated with implantation difficulty and suboptimal endograft fixation and/or sealing.

---

Medtronic does not represent or guarantee that this information is complete, accurate, or applicable to any particular patient or third party payor. The final decision of billing for any service must be made by the health care provider. Healthcare providers should consult with their own advisors regarding coding, coverage, and payment. CPT® is a trademark of the American Medical Association. UC202007864a EN ©2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution in the USA only. 12/2020.